Alina Jucov

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy

Michel Bazinet, Victor Pântea, Gheorghe Plăcintă et al. · Gastroenterology · 2020 · 232 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort

Zsuzsanna Végh, Johan Burisch, N Pedersen et al. · Journal of Crohn s and Colitis · 2015 · 40 citations · Full text

Medicine, Clinical Sciences, Surgery +10

Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis

Silvio Danese, Barrett G. Levesque, Brian G. Feagan et al. · Alimentary Pharmacology & Therapeutics · 2022 · 33 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection

Michel Bazinet, Victor Pântea, Gheorghe Plăcintă et al. · Journal of Hepatology · 2017 · 21 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy

Michel Bazinet, Mark Anderson, Victor Pântea et al. · Hepatology Communications · 2021 · 21 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17